Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Post by retiredcopon Sep 07, 2020 12:56pm
132 Views
Post# 31517949

Off our topic ..but amazing

Off our topic ..but amazing

Australian scientists have discovered that a unique molecule in the venom of honeybees is able to destroy aggressive breast cancer cells – without harming healthy cells.

ADVERTISING

A team from the Harry Perkins Institute of Medical Research and the University of Western Australia tested the venom from 312 honeybees and bumblebees from Australia, Ireland and England.

They extracted a peptide called melittin, which is what produces the acute pain from a bee sting, from the honeybees.

In a lab study on various subtypes of aggressive breast cancers, such as triple-negative breast cancer, the melittin was able to destroy 100 percent of tumours and cancerous cells.


<< Previous
Bullboard Posts
Next >>